Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- PAR-25-108
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.121 Oral Diseases and Disorders Research
- 93.395 Cancer Treatment Research
- 93.396 Cancer Biology Research
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- State Governments
- City/Township Governments
- Other
- For Profit Organizations
- Tribal Organizations (Not Federally Recognized)
- Tribal Governments (Federally Recognized)
- County Governments
- Non-501(c)(3) Nonprofits
- Public or Indian Housing Auth.
- 501(c)(3) Nonprofits
- Higher Education Inst. (Public)
- Small Businesses
- Higher Education Inst. (Private)
- Special District Governments
- Independent School Districts
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
This Notice of Funding Opportunity (NOFO) from the National Cancer Institute (NCI) seeks grant applications to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics, or diagnostics. The R21 funding mechanism is intended to support exploratory projects at an early conceptual stage to demonstrate the feasibility of the proposed approach. Eligible applicants include higher education institutions, state/local governments, non-profits, small businesses, and others. The grant program is associated with the Cancer Treatment Research, Oral Diseases and Disorders Research, and Cancer Biology Research federal grant programs.
The NOFO does not specify potential award values or budget ranges, but typical R21 exploratory research grants range from $200,000 to $400,000 in total costs over the 2-year project period. The research activities are expected to be conducted at the applicant organizations' facilities across the United States.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This NOFO will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. The R21 FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy, imaging, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-108-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity